Trumenba Meningococcal Vaccine Group B Injection Suspension 0.5 mL x 5/Box **Refrigeration Required

Trumenba is a groundbreaking vaccine designed to help prevent invasive disease caused by Neisseria meningitidis serogroup B, a serious and potentially deadly bacterial infection. As a leader in pharmaceutical innovation, Pfizer introduces this essential vaccine to offer robust protection, especially targeted at adolescents and young adults.

What is Trumenba Meningococcal Vaccine: 

Trumenba is a vaccine used to protect against invasive disease caused by Neisseria meningitidis serogroup B, a type of bacteria that can lead to serious illnesses like meningitis or bloodstream infections. It is approved for use in individuals aged 10 through 25 years. Trumenba works by stimulating the immune system to produce antibodies that target and neutralize the bacteria. It's typically recommended for people at increased risk for meningococcal disease, such as those in outbreak settings or with certain medical conditions. The vaccination schedule usually involves multiple doses.

Who Needs Trumenba Meningococcal Vaccine?

The Trumenba meningococcal vaccine is recommended for:

Adolescents and Young Adults: Primarily those aged 16 through 23 years, as this age group is at increased risk for meningococcal disease.

High-Risk Individuals:

• People with certain medical conditions, such as complement component deficiencies or functional or anatomical asplenia.
• Microbiologists routinely exposed to Neisseria meningitidis.
• Individuals part of a population experiencing a serogroup B meningococcal disease outbreak.

College Students and Military Recruits: Living in dormitories or similar close quarters, which can increase the risk of transmission.

Always consult with a healthcare provider to determine whether Trumenba is appropriate based on individual risk factors and health history.

How does Trumenba Meningococcal Vaccine Work

Trumenba works by stimulating the immune system to produce antibodies against Neisseria meningitidis serogroup B, the bacteria responsible for certain types of meningococcal disease. The vaccine contains proteins found on the surface of the bacteria. When the vaccine is administered, the immune system recognizes these proteins as foreign and generates antibodies. These antibodies help protect against the actual bacteria by targeting and neutralizing it, thus preventing infection if exposed in the future.

Product Details and Features

• Format: Injection Suspension
• Volume: 0.5 mL per dose
• Packaging: 5 doses per box
• Manufacturer: Pfizer US Pharmaceuticals Group (USPG)
• Target Population: Individuals aged 10–25 years
• Storage Requirements: Store in a refrigerator at 2°C to 8°C (36°F to 46°F). Do not freeze.

Mechanism of Action

Trumenba works by stimulating the immune system to produce antibodies against diverse serogroup B meningococcal strains. The vaccine contains two recombinant lipidated factor H binding protein (fHBP) variants, which trigger a strong and targeted immune response, aiding in the prevention of meningococcal disease.

Directions for Use

1. Dosage: Administer a 0.5 mL dose intramuscularly.
2. Schedule:
   • Standard immunization: 2 doses, administered six months apart.
   • Accelerated schedule: 3 doses, with the second dose given two months after the first, and the third dose four months after the second.

Warnings

• Allergy Warning: Do not administer to individuals with a known hypersensitivity to any component of the vaccine.
• Concurrent Illness: Postpone vaccination in individuals with moderate or severe acute illness until recovery.
• Immune Response: As with all protein-based vaccines, a protective immune response may not be elicited in all individuals.
• Syncope: The vaccine can cause fainting. Observe patients for 15 minutes post-vaccination.

Possible Side Effects

• Common Side Effects:

  • Pain at the injection site
  • Fatigue
  • Headache
  • Muscle pain
  • Chills
  • Redness or swelling at the injection site

• Severe Side Effects: Seek immediate medical attention if any of the following occur:

  • Severe allergic reactions (difficulty breathing, swelling of the face/lips/tongue)
  • High fever
  • Convulsions

Conclusion

Trumenba offers a critical line of defense for young individuals against the dangerous effects of meningococcal disease serogroup B. Trust in Pfizer’s dedication to safety and efficacy, ensuring peace of mind in protecting your health and wellbeing.